Spenser Lin No Comments

Healthcare News, Deals, and Investments Update Apr 20th, 2026

LECO_Weekly-Healthcare-News_4-20-2026Download

Healthcare Weekly News and Deals –April 20th, 2026

  1. White House Issues Executive Order to Accelerate Medical Treatments for Serious Mental Illness, with Focus on Psychedelic Research and Patient Access. The White House announced an executive order directing federal agencies to accelerate the research, development, and regulatory review of innovative treatments for serious mental illness, with particular emphasis on psychedelic compounds such as ibogaine for treatment-resistant cases. The order instructs the FDA to issue National Priority Vouchers for Breakthrough Therapy-designated psychedelic drugs, facilitates patient access under the Right to Try Act (including Schedule I substances), and allocates at least $50 million through ARPA-H for state partnerships and clinical trial support. It also calls for enhanced collaboration and data sharing with the VA, plus expedited rescheduling reviews for qualifying substances post-Phase 3. The action aims to address the mental health crisis impacting over 14 million U.S. adults and elevated suicide rates among veterans by promoting treatments offering enduring therapeutic benefits beyond traditional medications. (Link)
  2. McKesson (NYSE: MCK) Signs Agreement with Apollo Funds for $1.25 Billion Strategic Minority Interest in Medical-Surgical Solutions Business. McKesson Corporation (MCK) has entered into an agreement with Apollo Funds for a $1.25 billion investment in convertible preferred equity, representing an approximately 13% minority stake in its Medical-Surgical Solutions (MMS) business at a ~$13 billion enterprise valuation. McKesson will retain majority ownership, operating control, and financial consolidation of the unit. The transaction represents a key milestone in McKesson’s planned separation and future IPO of MMS, which supplies essential products and solutions to non-acute care settings. Apollo’s expertise in carve-outs is expected to support MMS as a well-capitalized standalone company. The deal remains subject to regulatory approvals. (Link)
  3. Global Medical Response (NYSE: GMRS) Files S-1 Registration Statement in Advance of Planned IPO. Global Medical Response (GMR Solutions Inc.) has filed an S-1 registration statement with the SEC for an initial public offering of Class A common stock on the NYSE under the symbol GMRS. The company, the largest U.S. provider of emergency medical services (EMS) and integrated alternate-site care, operates air and ground ambulances across approximately 1,400 counties and serves about 5.5 million patients annually with roughly 34,000 employees. For 2025, GMR reported net revenue of approximately $5.74 billion and Adjusted EBITDA of $1.19 billion. (Link)
  4. Eli Lilly (NYSE: LLY) Acquires Texas ADC Specialist CrossBridge Bio in ~$300 Million Deal to Strengthen Oncology Pipeline. Eli Lilly (LLY) has acquired Houston-based CrossBridge Bio, a preclinical antibody-drug conjugate (ADC) specialist, in a transaction valued at approximately $300 million (mix of upfront and milestones). CrossBridge’s technology, originating from the University of Texas Health Science Center, features advanced linker stability and multi-payload capabilities, with lead TROP2-targeting dual-payload candidate CBB-120 expected to enter the clinic in 2026. The deal further builds on Lilly’s recent ADC acquisitions and internal efforts, enhancing its position in next-generation cancer therapies. (Link)
  5. UCB to Acquire Neurona Therapeutics for Up to $1.15 Billion, Advancing Epilepsy Pipeline with Regenerative Cell Therapy. UCB has agreed to acquire Neurona Therapeutics, gaining its lead asset NRTX-1001, a pluripotent stem cell-derived neuronal cell therapy currently in Phase I/II trials for drug-resistant mesial temporal lobe epilepsy (mTLE). The total transaction value reaches up to $1.15 billion, including $650 million upfront and up to $500 million in potential milestones. The acquisition advances UCB’s leadership in epilepsy by introducing regenerative science approaches aimed at restoring neural circuitry and providing durable seizure control. NRTX-1001 has received FDA RMAT and EMA PRIME designations. The deal is expected to close by the end of Q2 2026, subject to antitrust clearance. (Link)
  6. Organon (NYSE: OGN) Shares Surge Following Reports of Acquisition Interest from Leading Private Equity Firms CVC Capital Partners and TPG. Organon (OGN) witnessed a 25% increase in its stock price amid market reports that CVC Capital Partners and TPG are exploring a potential multi-billion dollar acquisition of the company. The interest from these prominent private equity firms highlights the perceived value in Organon’s diverse portfolio of women’s health products, biosimilars, and established brands. While a formal deal has not been confirmed, the involvement of CVC and TPG suggests a significant investment opportunity in the pharmaceutical space, as financial sponsors look for stable, cash-flow-generative assets. Investors are keeping a close watch on OGN as potential bidding activities could reshape the women’s health sector. (Link)
  7. Avanos Medical, Inc. (NYSE: AVNS) Agrees to $1.272 Billion Acquisition by American Industrial Partners to Transition the Company into Private Ownership. Avanos Medical, Inc. (AVNS) has entered into a definitive agreement to be acquired by affiliates of American Industrial Partners (AIP) for approximately $1.272 billion in an all-cash transaction. AIP’s investment values Avanos at $25.00 per share, representing a significant premium for stockholders. The deal will transition Avanos into a private entity, allowing the company to focus on long-term growth and its innovation roadmap without public market pressures. AIP intends to leverage its deep operational expertise to enhance Avanos’s competitive position in the medical technology sector. The acquisition is expected to close in the second half of 2026, marking a new chapter for the medtech firm. (Link)
  8. Gyde Acquires Benavest, Marking Its Second Deal in Two Weeks as AI-Enabled Health Insurance Brokerage Expands. Gyde, an AI-powered health insurance brokerage platform that launched in January 2026 with $60 million in funding, has acquired Benavest, a national agency specializing in consumer health plans including individual ACA, ICHRA, and Medicare products. The deal follows Gyde’s recent acquisition of Medicare brokerage Avid Health. Benavest brings scalable distribution infrastructure and leadership expertise, which Gyde plans to support with its AI-driven GydeOS platform. No financial terms were disclosed. (Link)
  9. Signant Health, Supported by Financial Sponsors Harvest Partners, Genstar Capital, and Foresite Capital, Enters into a Definitive Agreement to Acquire Ametris. Signant Health has signed a definitive agreement to acquire Ametris, a global leader in digital health solutions, with the backing of private equity firms Harvest Partners, Genstar Capital, and Foresite Capital. This acquisition integrates Ametris’s clinical trial data management and sensor technologies into Signant’s evidence-generation platform. The move is a strategic play by the financial sponsors to consolidate the eClinical technology market, creating a more comprehensive suite of tools for pharmaceutical sponsors. By acquiring Ametris, Signant Health aims to enhance its capabilities in capturing high-quality clinical evidence across virtual, hybrid, and traditional trial models globally. (Link)
  10. BTX Precision, via Financial Sponsors L Squared Capital Partners and CFT Capital Partners, Completes the Strategic Acquisition of Maitland Engineering. BTX Precision has acquired Maitland Engineering to expand its precision manufacturing platform, supported by financial sponsors L Squared Capital Partners and CFT Capital Partners. This acquisition follows a series of strategic moves by BTX, including a recent continuation vehicle led by L Squared and backed by HarbourVest Partners. The investment in Maitland Engineering strengthens BTX Precision’s capabilities in producing complex, high-tolerance components for the medical and aerospace industries. L Squared Capital Partners continues to drive the platform’s buy-and-build strategy, focusing on integrating specialized regional manufacturers to create a dominant, national high-precision engineering entity with significant operational scale. (Link)
  11. CPIhealth, Supported by Financial Sponsor Iron Path Capital, Acquires Midwest Interventional Spine Specialists and Serenity Surgical Center. CPIhealth, a portfolio company of private equity firm Iron Path Capital, has acquired Midwest Interventional Spine Specialists (M.I.S.S.) and Serenity Surgical Center. This acquisition adds two clinical locations and an ambulatory surgery center to CPIhealth’s interventional pain management platform, expanding its presence in the Indiana and Illinois markets. Iron Path Capital’s investment facilitates the integration of five additional physicians and multiple nurse practitioners into the platform. This deal underscores the firm’s strategy of consolidating regional pain management practices to build a multi-state infrastructure capable of delivering advanced, cost-effective interventional spine care through a standardized clinical and administrative model. (Link)
  12. Brado AI Strengthens its Conversational Engagement Platform Through the Strategic Acquisition of ProviderIQ from Hatchleaf. Brado AI has acquired the ProviderIQ asset from Hatchleaf to enhance its precision routing and patient-provider matching capabilities. This acquisition allows Brado AI to integrate clinically informed data and real-world operational workflows into its Conversational Engagement Platform (CEP). By acquiring the technology co-developed with clinicians from Johns Hopkins, Brado AI is investing in more accurate demand-supply alignment for large healthcare systems. The deal reflects Brado AI’s commitment to reducing patient leakage and optimizing provider utilization. The investment highlights a growing trend of AI companies acquiring specialized clinical data tools to provide deeper insights and better ROI for health system partners. (Link)
  13. D2 Solutions Acquires PromodRx to Expand Patient Access and Engagement Technologies for Pharmaceutical and Medical Device Manufacturers. D2 Solutions has completed the acquisition of PromodRx, a cloud-based platform designed to accelerate patient access to prescription medications. This strategic investment expands D2 Solutions’ service offerings in market access, reimbursement support, and patient engagement. By integrating PromodRx’s technology, D2 Solutions strengthens its UltraTouch Verify and Engage platforms, helping pharmaceutical clients navigate complex prior authorization and benefit verification processes. The acquisition is intended to reduce therapy initiation delays and improve patient adherence, positioning D2 Solutions as a more comprehensive commercialization partner in an increasingly complex pricing and policy environment within the life sciences sector. (Link)
  14. H2 Health, a Portfolio Company of Grant Avenue Capital, Expands into Arkansas Through the Strategic Acquisition of Advanced Physical Therapy. H2 Health, backed by private equity firm Grant Avenue Capital, has acquired Advanced Physical Therapy (APT), a practice with six locations in the Little Rock, Arkansas market. This investment marks H2 Health’s expansion into a new state, bringing its total footprint to over 300 clinics across 13 states. Grant Avenue Capital continues to provide the financial resources for H2 Health’s aggressive buy-and-build strategy in the outpatient rehabilitation sector. The acquisition of APT allows H2 Health to leverage its centralized administrative infrastructure to improve operational efficiencies at the local level while expanding access to high-quality physical and occupational therapy services. (Link)
  15. Afterburner Capital and Council Capital Successfully Exit Their Investment in Advanced Care Partners Following an Eight-Year Growth Period. Private equity firms Afterburner Capital and Council Capital have announced the successful exit of their portfolio company, Advanced Care Partners (ACP). During their eight-year investment period, the sponsors helped ACP scale its pediatric and adult private duty nursing services across Georgia and Florida. The exit represents a significant milestone for Afterburner and Council Capital, who focused on professionalizing ACP’s management and clinical infrastructure to drive growth. This transaction highlights the strong investor demand for home-based care platforms that provide high-quality services to medically fragile populations, as financial sponsors seek exits that demonstrate successful clinical and operational scaling in the healthcare services market. (Link)
  16. Stellus Rx, a Portfolio Company of WindRose Health Investors, Acquires Tria Health to Create an Integrated Pharmacist-Led Chronic Care Platform. Stellus Rx, which is backed by WindRose Health Investors, has acquired Tria Health to expand its pharmacist-led pharmacy care management capabilities. This acquisition merges Stellus Rx’s dispensing solutions with Tria Health’s chronic condition support services for self-insured employers. WindRose Health Investors is supporting this combination to create a differentiated platform that reduces the total cost of care through improved medication adherence and clinical outcomes. The investment underscores WindRose’s strategy of backing companies that deliver cost-effective healthcare solutions. The unified entity aims to leverage shared data and clinical expertise to better manage complex patients across the healthcare continuum. (Link)
  17. Mobia Medical (MOBI) Files for a $100 Million Initial Public Offering Led by BofA Securities, J.P. Morgan, and Goldman Sachs to Advance its Vagus Nerve Stimulation Technology. Mobia Medical (MOBI), a developer of neurostimulation devices for chronic stroke recovery, has filed with the SEC to raise up to $100 million in an initial public offering. The IPO process is being led by joint bookrunners BofA Securities, J.P. Morgan, and Goldman Sachs, alongside BTIG and Wolfe | Nomura Alliance. The company, which generated $32 million in revenue in 2025, intends to use the proceeds to expand its commercial organization and fund further R&D for its Vivistim system. This filing signals a major step for the venture-backed company as it transitions into the public markets to capitalize on the $30 billion stroke recovery sector. (Link)

Venture Deals and Other

  1. Avo (AvoMD) Secures $10 Million Series A Funding Led by Noro-Moseley Partners with Participation from AlleyCorp, Las Olas Venture Capital, MedMountain Ventures, Epsilon Health, Scrub Capital, Dunamu & Partners, Mirae Asset Capital, and Futureplay. Avo (formerly AvoMD) has successfully closed a $10 million Series A funding round to advance its AI-powered clinical decision support platform. The round was led by Noro-Moseley Partners, featuring a broad syndicate of investors including AlleyCorp, Las Olas Venture Capital, MedMountain Ventures, Epsilon Health, and Scrub Capital. International support came from Korean firms Dunamu & Partners, Mirae Asset Capital, and Futureplay. The capital will be utilized to scale Avo’s generative AI copilots within major EHR systems, helping clinicians integrate real-time medical knowledge and hospital protocols directly into their digital workflows to improve patient outcomes. (Link)
  2. Bain Capital Life Sciences Backs Beeline Medicines with $300 Million in Capital to Develop Five Clinical Programs Acquired from Bristol Myers Squibb (BMY). Beeline Medicines has emerged from stealth with a massive $300 million investment commitment from Bain Capital Life Sciences. The venture-backed biotech is focused on advancing a portfolio of five clinical-stage programs originally discovered by Bristol Myers Squibb (BMY), targeting autoimmune and inflammatory diseases. This strategic investment allows Beeline to accelerate late-stage clinical development for assets like afimetoran, a TLR7/8 inhibitor. Bain Capital’s funding provides the necessary runway for Beeline to operate as an agile, clinical-stage entity, leveraging established pharmaceutical intellectual property to address significant unmet needs in the immunology and gastrointestinal sectors. (Link)
  3. Pulnovo Medical Announces Oversubscribed $100 Million Financing Round with Strategic Investment from Medtronic. Pulnovo Medical, a pioneer in innovative therapies for pulmonary hypertension, closed an oversubscribed $100 million financing round featuring a strategic investment from Medtronic. The capital will support the advancement of Pulnovo’s clinical programs and commercialization efforts for its pulmonary artery denervation technology. This marks a significant vote of confidence from one of the world’s leading medtech companies in the growing field of interventional pulmonary hypertension treatments. (Link)
  4. Joyful Health Raises $17 Million in Series A Funding Led by CRV with Support from XYZ Venture Capital, Designer Fund, Inflect Capital, and Go Global Ventures. Joyful Health, an AI-driven financial infrastructure provider for the healthcare industry, has secured $17 million in Series A funding. The investment was led by CRV, with participation from XYZ Venture Capital, Designer Fund, Inflect Capital, and Go Global Ventures. The company plans to use this capital to expand its workforce and accelerate the development of its “financial operating system,” which helps healthcare providers automate revenue cycle management and recover unpaid insurance claims. The investors highlighted Joyful Health’s ability to leverage AI to identify processing breakdowns and prioritize high-value recovery opportunities for resource-constrained medical practices. (Link)
  5. Keebler Health Announces $16 Million Series A Investment Led by Flare Capital Partners and Sands Capital to Expand AI Capabilities for Unstructured Clinical Data. Keebler Health has closed a $16 million Series A round led by Flare Capital Partners, with significant participation from Sands Capital. The funding will scale Keebler’s LLM-native platform, which is designed to unlock insights from unstructured clinical documentation—such as provider notes and imaging reports—to improve risk adjustment and value-based care accuracy. Investors noted that Keebler’s technology addresses a critical gap in the market where 80% of patient data remains underutilized. This capital injection will support team expansion and the deployment of real-time clinical insights aimed at enhancing both financial performance and patient outcomes for healthcare systems. (Link)
  6. Worki Secures $2.75 Million in Pre-Seed Funding Led by Founders Fund and Y Combinator to Scale its Healthcare Recruitment and Workforce Management Platform. Healthcare staffing startup Worki has raised $2.75 million in a pre-seed round led by Founders Fund and Y Combinator. The investment targets the growing labor crisis in healthcare by providing a mobile-first platform that simplifies recruitment and scheduling for both providers and facilities. Founders Fund and Y Combinator are backing Worki’s mission to reduce industry reliance on expensive third-party staffing agencies through a more streamlined, automated hiring process. The new capital will be used to enhance the platform’s AI-driven matching capabilities and expand its reach across North American health systems struggling with nurse and technician shortages. (Link)
Spenser Lin No Comments

Healthcare News, Deals, and Investments Update Apr 13th, 2026

LECO_Weekly-Healthcare-News-4-13-2026Download

Healthcare Weekly News and Deals –April 13th, 2026

  1. FunctionHealth, a longevity-focused health tech startup for at-home-accessible lab testing, has acquired mobile healthcare platform Getlabs to bring comprehensive diagnostic services directly to consumers’ homes. Function, a health-tech company focused on proactive wellness, has acquired Getlabs, the leader in nationwide at-home lab draws. This acquisition allows Function to integrate a physical service layer into its digital platform, enabling members to have blood work and other diagnostics performed in the comfort of their homes. The investment is aimed at removing the friction traditionally associated with laboratory testing. By owning the logistical infrastructure of Getlabs, Function can ensure a standardized, high-quality experience for its users, furthering its mission to empower individuals with deep health insights through regular and accessible testing. (Link)
  2. Havencrest Capital Management has completed a majority recapitalization of Offor Health to accelerate the expansion of its clinical delivery model. Havencrest Capital Management, a healthcare-focused private equity firm, has finalized a majority recapitalization of Offor Health. This investment is designed to provide the necessary growth capital for Offor Health to scale its unique model of delivering high-quality clinical care, particularly in the dental and specialized surgical spaces. Havencrest’s involvement will focus on enhancing the company’s operational infrastructure and geographic footprint. The investor views Offor Health as a disruptive force in office-based clinical services, and the capital infusion will support the company’s mission to increase patient access and reduce costs for specialized procedures. (Link)
  3. ESO, backed by financial sponsors Vista Equity Partners and JSL Health Capital, has successfully acquired d2i to accelerate emergency intelligence and improve outcomes across fire, EMS, and health systems. ESO, a leading data and software vendor for emergency medical services (EMS), fire departments, and hospitals, has finalized its acquisition of d2i. The investment, supported by PE firms Vista Equity Partners and JSL Health Capital, aims to integrate d2i’s advanced data analytics and performance management tools into ESO’s ecosystem. This move is designed to provide healthcare professionals with deeper insights into clinical and operational performance. The investors are focused on scaling ESO’s ability to drive better patient outcomes through real-time data intelligence across the continuum of care. (Link)
  4. Council Capital and PMPK have partnered to acquire MedicalServiceQuotes.com to expand their healthcare procurement and analytics platform capabilities. Council Capital, a healthcare-focused private equity firm, alongside PMPK, has acquired MedicalServiceQuotes.com (MSQ). The investment is intended to bolster MSQ’s position as a leading platform for healthcare procurement, providing transparency and efficiency in medical service sourcing. By integrating Council Capital’s deep industry expertise and PMPK’s strategic resources, the company plans to scale its analytics and procurement tools. The investors aim to capitalize on the growing demand for cost-containment solutions in the healthcare sector, helping providers and payers optimize their spend through a more streamlined, data-driven digital marketplace. (Link)
  5. Qualifacts Systems, supported by financial sponsors Warburg Pincus, Martis Capital Management, and Clanton Capital, has completed the acquisition of MethodOne to enhance its behavioral health technology offerings. Qualifacts, a leading provider of electronic health records (EHR) for behavioral health, has expanded its portfolio by acquiring MethodOne. The deal is backed by a powerful consortium of investors including Warburg Pincus, Martis Capital, and Clanton Capital. MethodOne specializes in comprehensive clinic management software for opioid treatment programs. The investors are betting on the consolidation of specialized behavioral health software to create a unified platform that addresses the complex regulatory and clinical needs of addiction treatment providers. This acquisition strengthens Qualifacts’ market position as a premier technology partner in the behavioral health and human services sectors. (Link)
  6. Bioness Medical, via its financial sponsor Accelmed, has acquired the Portable Neuromodulation Stimulator (PoNS) system to bolster its neuro-rehabilitation portfolio. Bioness Medical, a subsidiary supported by the private equity firm Accelmed, has successfully acquired the PoNS system, a non-invasive medical device used in neurological rehabilitation. Accelmed’s strategic investment is aimed at integrating this innovative technology into Bioness’s existing suite of rehabilitation solutions. The acquisition allows Bioness to offer a more comprehensive range of therapies for patients suffering from neurological symptoms due to disease or trauma. Accelmed plans to utilize its expertise in the medical device sector to drive the commercial adoption and clinical validation of the PoNS system in global markets. (Link)
  7. DAS Health, backed by financial sponsor Coalesce Capital, has expanded its national footprint through the acquisition of Prime Care Technologies and Prime Cloud from Prime Holdings. DAS Health, a leader in healthcare IT and management services, has acquired Prime Care Technologies and Prime Cloud. This transaction was facilitated by Coalesce Capital, which provides the strategic funding and guidance for DAS Health’s aggressive expansion strategy. The acquisition integrates advanced cloud hosting and post-acute care technology solutions into DAS Health’s portfolio, enhancing its service offerings for long-term care facilities. Coalesce Capital is focused on building DAS Health into a dominant national provider of healthcare technology solutions, leveraging the synergies between these entities to offer comprehensive, integrated services to a wider range of medical providers. (Link)
  8. Sidekick Therapy Partners, supported by financial sponsors Green Hills Partners and Hillandale Advisors, has acquired Word of Mouth Clinical Associates to broaden its therapy service delivery. Sidekick Therapy Partners, a provider of pediatric therapy services, has acquired Word of Mouth Clinical Associates. The deal is backed by Green Hills Partners and Hillandale Advisors, who are focused on consolidating the fragmented pediatric therapy market. By acquiring Word of Mouth, Sidekick expands its reach and clinical expertise in speech, occupational, and physical therapy. The investors are committed to supporting Sidekick’s growth through operational improvements and strategic bolt-on acquisitions. This move strengthens Sidekick’s ability to provide high-quality, multidisciplinary care to children and families while creating a larger, more efficient regional platform. (Link)
  9. Livtech has successfully acquired Alora Healthcare Systems to integrate advanced home health software into its technology ecosystem. Livtech, a prominent player in healthcare technology, has announced the acquisition of Alora Healthcare Systems. This strategic acquisition focuses on Alora’s specialized software solutions for home health agencies. The investment is intended to create a more robust, end-to-end platform for home-based care providers, streamlining clinical documentation, scheduling, and billing. By integrating Alora’s technology, Livtech aims to provide a seamless user experience for healthcare professionals operating outside of traditional hospital settings. The acquisition reflects the increasing investment interest in home health technology as the industry shifts toward decentralized, patient-centric care models. (Link)
  10. Vertex Pharmaceuticals (NASD: VRTX) has entered into a definitive agreement to acquire Alpine Immune Sciences (NASD: ALPN) for approximately $4.9 billion to bolster its immunology pipeline. Vertex Pharmaceuticals is set to acquire Alpine Immune Sciences in an all-cash deal, significantly expanding its presence in the immunology and immunotherapy space. The acquisition centers on Alpine’s lead candidate, povetacicept, a potential best-in-class treatment for various autoimmune diseases. Vertex is utilizing its strong balance sheet to invest in high-potential late-stage clinical assets that complement its existing focus on serious diseases. This multi-billion dollar investment underscores Vertex’s strategy of diversifying beyond cystic fibrosis and acquiring innovative platforms that can address significant unmet medical needs in the protein engineering and immunology sectors. (Link)
  11. MKH Capital Partners has acquired Haven Health Management to provide growth capital for its 22 treatment locations across the United States. MKH Capital Partners, a family-backed private equity firm, has completed the acquisition of Haven Health Management. The investment provides significant growth capital to support Haven Health’s operations across its 22 addiction and mental health treatment facilities. MKH Capital Partners intends to use its resources to expand Haven Health’s geographic footprint and enhance its clinical services. The investor sees a substantial opportunity in the behavioral health sector, focusing on improving patient access to evidence-based treatment for substance use disorders. This deal highlights the continued interest of private equity in scaling established behavioral health platforms. (Link)
  12. Gilead Sciences, Inc. (NASD: GILD) has announced the acquisition of Tubulis to add a next-generation antibody-drug conjugate (ADC) platform to its oncology pipeline. Gilead Sciences is acquiring Tubulis to gain access to its proprietary ADC technologies, which are designed to create more stable and effective cancer therapies. This strategic investment is part of Gilead’s ongoing effort to diversify its portfolio into oncology and become a leader in targeted cancer treatments. The acquisition includes Tubulis’s diverse pipeline of ADC candidates and its innovative conjugation platforms. Gilead intends to leverage its extensive clinical development and commercialization expertise to accelerate the progress of Tubulis’s candidates, further strengthening its position in the rapidly evolving and highly competitive ADC market. (Link)
  13. BPOC has completed the sale of Midwest Products Engineering (MPE), marking the conclusion of a successful investment period for the private equity firm. BPOC, a healthcare-focused private equity firm, has finalized the sale of Midwest Products Engineering (MPE). During BPOC’s ownership, MPE expanded its capabilities as a leading design and manufacturing partner for medical device OEMs. The firm’s investment supported MPE’s growth through operational enhancements and strategic initiatives, positioning it as a critical supplier in the medical equipment market. This exit demonstrates BPOC’s ability to build value within the medical manufacturing sector. While the buyer was not disclosed, the sale highlights the strong demand for specialized manufacturing firms that serve the high-growth medical device industry. (Link)
  14. Response BPO has joined Carenet Health to exponentially grow its U.S. healthcare impact through expanded operations in South Africa. Carenet Health, a provider of 24/7 healthcare engagement and clinical solutions, has acquired Response BPO. This investment is strategically aimed at leveraging Response BPO’s operational strength in South Africa to enhance Carenet Health’s service delivery for U.S.-based healthcare organizations. The acquisition allows Carenet to offer more cost-effective and scalable engagement solutions, including clinical support and member services. By integrating Response BPO, Carenet Health strengthens its global delivery model, ensuring high-quality, continuous support for its clients while expanding its international footprint in the competitive business process outsourcing market within the healthcare sector. (Link)
  15. Telcor has acquired Sample Healthcare to lead an AI-driven transformation of revenue cycle operations for healthcare providers. Telcor, a leader in laboratory revenue cycle management (RCM) and point-of-care testing software, has acquired Sample Healthcare. This investment is focused on integrating Sample Healthcare’s AI capabilities into Telcor’s existing RCM platform. The goal is to automate complex billing processes, reduce denials, and improve the financial performance of laboratories and health systems. The investors believe that applying AI to revenue cycle operations will significantly increase efficiency and accuracy in healthcare billing. This acquisition reinforces Telcor’s position as an innovator in the RCM space, providing its clients with advanced tools to navigate the complexities of healthcare reimbursement. (Link)
  16. Blackstone and TPG Capital have completed the multi-billion dollar acquisition of medical technology leader Hologic, Inc. (NASD: HOLX). Private equity giants Blackstone and TPG have finalized their acquisition of Hologic, a prominent developer of diagnostic products and medical imaging systems. This strategic move aims to leverage Hologic’s market leadership in women’s health and surgical products to drive further innovation and global expansion. The investors plan to support the company’s R&D initiatives and enhance its operational capabilities through their extensive network and capital resources. This acquisition reflects the ongoing interest of top-tier private equity firms in high-performing medical technology assets with steady revenue streams and significant growth potential in the global diagnostics market. (Link)
  17. Seaport Therapeutics, a PureTech Health (LSE: PRTC) founded entity, has filed for a U.S. Initial Public Offering (IPO) to fund the development of its neuropsychiatric pipeline. Seaport Therapeutics, established by the biotherapeutics company PureTech Health, has officially filed for an IPO in the United States. The company is focused on advancing a pipeline of novel neuropsychiatric medicines using its proprietary Glyph platform, which is designed to enhance the oral bioavailability of drugs. The IPO proceeds are intended to fund clinical trials and further research into treatments for depression, anxiety, and other central nervous system disorders. This move marks a significant milestone for Seaport and its founding investors, as they seek to transition from a venture-backed entity to a public company to access broader capital markets for long-term growth. (Link)
  18. APM Human Services International Limited (ASX: APM) has acquired WorkCare to expand its occupational health and workforce wellness solutions across the global health and human services market WorkCare, a leading provider of occupational health and incident management services, has been acquired by APM Human Services International Limited (ASX: APM). This strategic acquisition allows APM to significantly bolster its “Health and Wellbeing” service vertical, integrating WorkCare’s clinical expertise in medical surveillance, onsite clinics, and telehealth. The investment is focused on scaling WorkCare’s delivery model across the United States and international markets, leveraging APM’s global infrastructure. The deal reflects the investor’s objective to address the increasing demand for integrated, data-driven employee health solutions that reduce workplace injuries and improve organizational productivity on a global scale. (Link)

Venture Deals and Other

  1. Chapter has raised $100 million in a new funding round led by Addition and NFX to simplify the Medicare enrollment process for seniors. Chapter, a technology-driven Medicare advisor, has secured $100 million in growth capital to expand its platform. The round was led by venture capital firms Addition and NFX, with participation from other existing investors. This significant investment will be used to enhance Chapter’s proprietary technology, which helps seniors navigate the complexities of Medicare to find the best-fitting coverage. The investors are backing Chapter’s unique model that searches every available plan, unlike traditional brokers. The capital will also support the hiring of additional advisors and the expansion of the company’s reach to more seniors across the United States. (Link)
  2. HeyDonto has closed a $20 million Seed round at a $200 million valuation to scale Conduit, its innovative dental interoperability exchange platform. HeyDonto, an AI-focused dental technology startup, has raised $20 million in Seed funding from a group of strategic venture investors. The round values the company at $200 million, reflecting strong investor confidence in its Conduit platform. Conduit is designed to solve the long-standing problem of data silos in dentistry by providing a seamless interoperability exchange for patient records and clinical data. The investment will be used to accelerate product development and expand the company’s sales and marketing efforts. The investors aim to position HeyDonto as the central infrastructure for the modern, data-driven dental practice, improving efficiency and patient care. (Link)
  3. SimpliFed has raised over $10 million in an oversubscribed Series A round to expand its maternal health ecosystem and improve access to breastfeeding support. SimpliFed, a maternal health company, has successfully closed a Series A funding round exceeding $10 million. The oversubscribed round included participation from several venture capital firms focused on health-tech and female-founded businesses. SimpliFed provides virtual breastfeeding support and baby feeding guidance, covered by insurance. The new capital will be used to scale the company’s operations, partner with more health plans, and expand its team of clinical experts. Investors are particularly interested in SimpliFed’s ability to provide high-quality, accessible maternal care that improves long-term health outcomes for both mothers and infants while reducing overall healthcare costs. (Link)
  4. Luminai has raised $38 million in a Series B funding round to scale its intelligence platform across health system operations and administrative workflows. Luminai, a company specializing in operational intelligence for healthcare, has secured $38 million in Series B funding. The round was led by prominent venture capital firms looking to capitalize on the automation of healthcare administration. Luminai’s platform uses AI to streamline complex workflows within health systems, reducing the administrative burden on staff and improving operational efficiency. The investment will be used to expand the company’s product features and accelerate its market penetration among large health systems. The investors see Luminai as a key player in solving the staffing shortages and burnout issues currently plaguing the healthcare industry through smart automation. (Link)
  5. Yuzu Health, a next-generation third-party administrator (TPA) providing unified infrastructure for health insurance plans, has raised $35 million in Series A funding. The round was led by General Catalyst and Chemistry, with participation from Anthropic’s Anthology Fund and others. The platform enables customizable plan designs through white-labeled claims processing, payments, and member administration. Proceeds will expand the engineering team and automate manual workflows to scale nationally. Investors see Yuzu Health as a key modernizer of outdated  infrastructure. (Link)
  6. Jimini Health, a clinician-supervised AI platform for behavioral health, has raised $17 million in seed funding led by M13 and Town Hall Ventures. Its Sage assistant integrates into care teams with full clinician oversight and visibility. The capital will support enterprise partnerships, expand clinical capabilities, and deepen EHR integrations. Investors view Jimini Health as a safe, scalable solution to responsibly deploy AI in mental health while addressing risks of unsupervised tools. (Link)
Spenser Lin No Comments

Healthcare News, Deals, and Investments Update Mar 30th, 2026

LECO_Weekly-Healthcare-News_3-30-2026Download
  1. Abbott (NYSE: ABT) Completes Acquisition of Exact Sciences (NASDAQ: EXAS) Abbott (NYSE: ABT) has officially finalized its acquisition of Exact Sciences (NASDAQ: EXAS), a move aimed at bolstering its leadership in the cancer diagnostics and screening market. The integration of Exact Sciences’ flagship Cologuard technology into Abbott’s massive global diagnostics portfolio is expected to drive significant revenue growth and expand access to non-invasive screening tools. Investors are monitoring how this multibillion-dollar deal will impact Abbott’s long-term earnings per share. This strategic consolidation highlights the ongoing trend of medical device giants acquiring specialized biotech innovators to maintain a competitive edge in the preventive healthcare sector. (Link)
  2. Merck (NYSE: MRK) to Acquire Terns Pharmaceuticals (NASDAQ: TERN) for $53 Per Share in Cash Merck (NYSE: MRK) has entered into a definitive agreement to acquire Terns Pharmaceuticals (NASDAQ: TERN) for $53 per share in an all-cash transaction. This acquisition allows Merck to gain control of Terns’ promising pipeline of oncology and metabolic disease treatments, specifically focusing on small-molecule oral therapies. The premium price reflects investor confidence in Terns’ clinical data and the potential for these assets to offset upcoming patent expirations in Merck’s existing portfolio. The deal reinforces Merck’s aggressive M&A strategy to diversify its pipeline through high-value biotech acquisitions that offer immediate technological advantages and long-term market exclusivity. (Link)
  3. Infosys (NYSE: INFY) to Acquire US Firms Optimum Healthcare IT for $465 Million and Stratus for $95 Million Infosys (NYSE: INFY) is significantly expanding its footprint in the United States healthcare sector by acquiring Optimum Healthcare IT for $465 million and Stratus for $95 million. These investments are designed to enhance Infosys’ digital transformation capabilities, specifically within healthcare provider networks and cloud-based medical data management. By bringing these specialized consulting firms under the Infosys umbrella, the company aims to offer more robust, end-to-end IT solutions to American healthcare systems. Investors view this as a strategic deployment of capital to capture the growing demand for digital modernization and data interoperability within the heavily regulated healthcare industry. (Link)
  4. Cencora (NYSE: COR) to Expand Retina Consultants of America Through Acquisition of EyeSouth Partners’ Retina Business Cencora (NYSE: COR), formerly AmerisourceBergen, has announced a deal to acquire the retina-specific business of EyeSouth Partners to expand its Retina Consultants of America (RCA) platform. EyeSouth Partners is backed by Olympus Partners. This acquisition underscores Cencora’s commitment to specialized physician services, particularly in the high-growth ophthalmology sector. By integrating these practices, Cencora enhances its scale in clinical research and specialty distribution, providing a more comprehensive value proposition to manufacturers and patients alike. The investment reflects a broader private equity-style roll-up strategy within the specialty care market, aimed at optimizing operational efficiencies and expanding the company’s geographic reach across the United States. (Link)
  5. Efferent Acquired by Hopper OS via Financial Sponsor GPI Capital Through an LBO Efferent was acquired by Hopper OS on March 24, 2026, through a leveraged buyout (LBO) backed by financial sponsor GPI Capital. This acquisition is intended to integrate Efferent’s specialized technology into Hopper OS’s “intelligent healthcare operating system,” creating a more seamless data environment for providers. GPI Capital’s involvement indicates a strong private equity interest in the healthcare infrastructure space, focusing on companies that can automate clinical workflows. The undisclosed investment will facilitate the scaling of Efferent’s tools, allowing Hopper OS to offer a more robust, AI-enhanced suite of products to its global healthcare clientele. (Link)
  6. HealthTech Solutions Acquired by Health Management Associates via Financial Sponsor BPOC Through an LBO Health Management Associates (HMA) has completed the acquisition of HealthTech Solutions through a leveraged buyout supported by financial sponsor BPOC. The deal, finalized on March 27, 2026, aims to merge HMA’s Medicaid expertise with HealthTech’s advanced technological capabilities. BPOC’s investment highlights the private equity sector’s focus on Medicaid modernization and state-level healthcare IT. By acquiring HealthTech, HMA strengthens its ability to provide technical advisory services to government agencies. The undisclosed transaction is expected to drive growth by enabling HMA to manage complex data systems and improve health outcomes for vulnerable populations through better technology. (Link)
  7. Careflow Receives Growth Investment from Blueprint Equity to Expand Product Platform Careflow has secured an undisclosed amount of development capital from Blueprint Equity as of March 26, 2026. This strategic growth investment is earmarked for the expansion of Careflow’s product platform and the acceleration of its market penetration. Blueprint Equity’s participation marks a significant vote of confidence in Careflow’s software solutions for the healthcare industry. The capital infusion will allow the company to scale its operations and enhance its technological offerings, focusing on improving workflow efficiency for healthcare professionals. This deal exemplifies the active role of private equity in fostering the growth of mid-sized health-tech firms aiming for market leadership. (Link)
  8. Novartis to Acquire Excellergy in Up to $2B Deal to Expand Allergy Pipeline Novartis has agreed to acquire Excellergy, a U.S.-based biotech developing next-generation therapies for allergic diseases, in a deal worth up to $2 billion including milestone payments. The acquisition adds Excellergy’s lead asset, Exl-111, a next-generation anti-IgE antibody currently in early-stage clinical development, designed to deliver faster and more durable suppression of allergic responses. Exl-111 builds on the same biological pathway as Novartis’ blockbuster Xolair but is engineered to improve efficacy, dosing convenience, and overall disease control across multiple IgE-mediated conditions. The transaction is expected to close in the second half of 2026, pending regulatory approvals, further strengthening Novartis’ leadership in immunology and allergy therapeutics. (Link)
  9. PCSI Completes Acquisition of CareStarter and Feedback to Launch PCSIx Innovation Unit PCSI has finalized the acquisition of CareStarter and Feedback, two companies focused on patient engagement and care coordination. These acquisitions serve as the foundation for PCSI’s new innovation unit, PCSIx. The investment aims to bridge the gap between healthcare providers and patients by utilizing CareStarter’s resource platforms and Feedback’s communication tools. By consolidating these technologies, PCSI intends to streamline the patient journey and improve health literacy. This move signals a shift toward integrated, patient-centered care models, with the investor focusing on long-term value through improved patient outcomes and reduced administrative friction in the care delivery process. (Link)
  10. Collectly to Acquire Pledge Health to Accelerate AI Automation in Patient Finance Collectly has announced its acquisition of Pledge Health, a strategic move designed to integrate AI-driven automation into the patient financial experience. The acquisition focuses on streamlining medical billing and transparent pricing, addressing one of the most significant pain points in American healthcare. By combining forces, Collectly and Pledge Health aim to provide patients with clearer financial insights while helping providers increase collection rates through automated workflows. This investment highlights the growing market for fintech solutions within the healthcare sector, where AI is being leveraged to reduce manual errors and improve the overall transparency of healthcare costs. (Link)
  11. Vitality Acquires Ramp Health to Merge AI Behavioral Health and Workplace Safety Vitality has successfully acquired Ramp Health, aiming to create a comprehensive platform that merges AI-powered behavioral health services with workplace safety protocols. This acquisition is part of Vitality’s broader strategy to enhance corporate wellness programs by providing employers with data-driven tools to support employee mental and physical health. The integration of Ramp Health’s expertise allows Vitality to offer more personalized health interventions and preventative safety measures. Investors see this as a timely move, given the increasing corporate focus on employee well-being and the role of AI in delivering scalable health solutions in a professional environment. (Link)
  12. Palm Primary Care Acquires Two Clinics in Azle to Expand Local Access Palm Primary Care has expanded its clinical footprint by acquiring two primary care clinics in Azle, Texas. This investment is part of the company’s localized growth strategy, focusing on increasing access to high-quality primary care in suburban and rural areas. By acquiring established practices, Palm Primary Care can immediately serve an existing patient base while implementing its standardized care models and advanced technology systems. The deal reflects a continuing trend of consolidation in the primary care sector, where larger organizations acquire independent practices to achieve economies of scale and provide more integrated services to the local community. (Link)
  13. HealthDrive Corp Acquires Georgia Long-Term Care Consulting HealthDrive Corp, backed by Cressey & Company, has acquired Georgia Long-Term Care Consulting, expanding its reach into the specialized field of post-acute and long-term care services. This acquisition allows HealthDrive to strengthen its consultancy and on-site clinical service offerings for seniors in long-term care facilities. The investment is driven by growing demand for specialized medical services within the aging population. By integrating the Georgia-based firm, HealthDrive enhances its ability to manage complex care needs and regulatory compliance for long-term care facilities. This move reinforces HealthDrive’s position as a major player in the evolving landscape of senior healthcare services in the United States. (Link)
  14. Cerebral Acquires Inflow to Broaden Mental Health and ADHD Support Cerebral has acquired Inflow, a startup focused on digital tools for ADHD management, to broaden its behavioral health platform. This acquisition enables Cerebral to provide more specialized, non-clinical support for neurodivergent individuals, complementing its existing telepsychiatry services. The investment highlights Cerebral’s strategy to become a holistic provider of mental health solutions by incorporating self-management tools and community support into its clinical model. Investors are watching how this expansion into digital therapeutics will help Cerebral differentiate itself in a crowded telehealth market while improving long-term patient engagement and clinical outcomes for those with ADHD. (Link)
  15. Gilead Sciences to Acquire Ouro Medicines in $2.2B Deal to Expand Autoimmune Pipeline Gilead Sciences announced it will acquire Ouro Medicines in a transaction valued at up to approximately $2.2 billion, including $1.675 billion upfront and potential milestone payments. The deal centers on Ouro’s lead asset, a clinical-stage BCMAxCD3 T-cell engager designed to treat severe autoimmune diseases by targeting pathogenic B cells. Early data has shown promising efficacy and a differentiated safety profile, positioning the therapy as a potential “immune reset” approach. Strategically, the acquisition expands Gilead’s inflammation and immunology pipeline as it seeks to diversify beyond its core HIV franchise. (Link)
  16. RTW Investments Boosts Stake in Cogent Biosciences RTW Investments increased its position in U.S.-based Cogent Biosciences by purchasing over 4.1 million shares, representing an estimated $116 million investment and signaling strong conviction in the company’s pipeline. The stake now accounts for roughly 2.7% of RTW’s reportable assets, highlighting the importance of the position within its biotech-focused portfolio. Cogent is advancing precision therapies for genetically defined diseases, with key U.S. regulatory milestones, including an FDA decision expected in late 2026, acting as major value inflection points. The move reflects continued investor interest in U.S. biotech innovation, particularly companies nearing potential commercialization. (Link)
  17. GeBBS Healthcare Solutions Announces Acquisition of RND OptimizAR GeBBS Healthcare Solutions, Inc., a leading provider of technology-enabled Revenue Cycle Management (RCM) and Risk Adjustment Solutions for healthcare providers and payers, announced this morning the acquisition of RND OptimizAR, an India-based specialized provider of Revenue Cycle Management services focused on the Durable Medical Equipment (DME) and Home Medical Equipment (HME) market. The deal strengthens GeBBS’ capabilities in niche RCM segments. GeBBS is backed by global investors including EQT and ChrysCapital. (Link)
  18. Vision Innovation Partners Acquires Frederick Eye Institute Vision Innovation Partners (VIP), a leading Mid-Atlantic eye care platform with 69 locations and backed by Gryphon Investors, announced this morning the acquisition of Frederick Eye Institute, a comprehensive ophthalmology practice in Frederick, Maryland. This marks VIP’s 28th add-on acquisition since 2017 and further strengthens its presence in the key Maryland. (Link)
  19. AI Maverick Intel Announces LOI to Acquire HEAL Access Canada  The proposed acquisition would integrate HEAL’s AI-powered patient navigation and virtual care coordination platform into its ecosystem. The deal represents the first transaction under its Right of First Refusal agreement with HEAL. (Link)
  20. Monument MicroCap Partners Invests in Champion Wellness Centers to Support Growth and Expansion The investment supports Champion Wellness Centers, a Tampa-based provider of chiropractic and multidisciplinary wellness services. The company operates a network of clinics offering physical therapy, regenerative medicine, and other integrated treatments, positioning it to benefit from growing demand for holistic care. The partnership will support geographic expansion and add-on acquisitions. (Link)

Venture Deals and Other

  1. eMed Raises $200 Million Led by Aon, Including Participation from Tom Brady and Linda Yaccarino to Expand GLP-1 Access eMed has received a strategic investment from a high-profile group including Tom Brady and Linda Yaccarino to support its mission of expanding access to GLP-1 weight-loss medications. The funding will enhance eMed’s digital health platform, which provides clinical oversight and testing for patients seeking metabolic treatments. This investment reflects the massive market demand for weight-loss drugs and the role of telehealth in managing prescription distribution. The involvement of such prominent figures suggests a shift toward celebrity-backed healthcare ventures that aim to combine medical credibility with mass-market consumer appeal in the rapidly growing obesity-treatment sector. (Link)
  2. Adonis Raises $40 Million in Series C Funding to Transform Revenue Cycle Management Adonis has successfully closed a $40 million Series C funding round to accelerate the development of its AI-driven revenue cycle management platform. This significant capital infusion will be used to enhance the company’s automation capabilities, helping healthcare providers reduce administrative burdens and improve billing accuracy. The investment round reflects strong venture capital confidence in Adonis’s ability to solve complex financial inefficiencies within the healthcare system. With this new funding, Adonis plans to expand its engineering team and scale its go-to-market strategies, aiming to become the standard for financial operations in large-scale medical groups and health systems. (Link)
  3. Blossom Health Secures Series A Funding Led by Headline to Expand Telepsychiatry Services Blossom Health has raised a Series A investment round, with Headline serving as the lead investor. The funding is intended to scale Blossom Health’s telehealth and telepsychiatry platform, which focuses on providing accessible mental healthcare to underserved populations. Headline’s involvement brings both capital and strategic expertise in scaling consumer-facing digital health brands. Blossom Health plans to use the funds to hire more clinical staff and enhance its mobile application interface. This deal highlights the continued venture capital appetite for mental health startups that leverage technology to overcome traditional barriers to care, such as cost and geographic location. (Link)
  4. Dimer Health Raises $13.5 Million for AI-Driven Post-Discharge Care Platform Dimer Health has secured $13.5 million in funding to support its AI-driven platform designed to improve post-discharge patient care. The investment will be used to further develop technology that monitors patients after they leave the hospital, aiming to reduce readmission rates and improve recovery outcomes. By utilizing predictive analytics, Dimer Health helps clinicians identify high-risk patients who may need immediate intervention. This venture deal underscores the growing interest in “hospital-at-home” models and the use of artificial intelligence to bridge the gap between acute hospital stays and long-term recovery in a home setting. (Link)
  5. Gimlet Labs Raises $80 Million to Transform AI Inference Infrastructure Gimlet Labs has closed a substantial $80 million funding round aimed at transforming AI inference infrastructure. While not strictly a healthcare firm, its technology is pivotal for the future of AI-driven medical diagnostics and drug discovery. The investment will allow Gimlet Labs to scale its hardware and software solutions that make running complex AI models faster and more cost-effective. Venture capitalists are betting on Gimlet Labs to provide the foundational infrastructure that will power the next generation of AI applications across various sectors. This capital will be used for research and development and expanding their manufacturing capabilities to meet global demand. (Link)
Spenser Lin No Comments

Healthcare News, Deals, and Investments Update Feb 2nd, 2026

LECO_Weekly-Healthcare-News_2-2-2026Download
  1. Boston Scientific (NYSE: BSX) completes $600M acquisition of Nalu Medical to deepen neuromodulation portfolio for chronic pain The deal adds Nalu’s miniaturized, battery‑free implantable pulse generator for spinal cord and peripheral nerve stimulation, wirelessly powered by an external wearable disc and controlled via smartphone, with an expected 18‑year service life. Nalu’s system, cleared initially by the FDA in 2019 and later for whole‑body MRI use, delivers neuromodulation for chronic neuropathic pain with capabilities comparable to larger IPGs. Boston Scientific projects Nalu revenue above $60 million in 2025 with more than 25% growth in 2026 and expects the transaction to become increasingly accretive to earnings after 2027. (Link)
  2. Laborie acquires JADA System for $465M, backed by Patricia Industries to strengthen its global maternal health and postpartum haemorrhage care portfolio The acquisition brings an FDA-cleared device for rapid control of abnormal postpartum uterine bleeding into Laborie’s comprehensive obstetrics portfolio spanning antepartum through neonatal care. JADA uses low-level vacuum to stimulate natural uterine contractions, helping stop postpartum haemorrhage quickly and effectively and has already been used in more than 136,000 mothers across over 20 countries, supported by multiple safety and effectiveness studies. Laborie will onboard over 90 primarily commercial team members as part of a long-term strategy to back innovations that improve maternal outcomes and support sustainable growth. (Link)
  3. Halozyme Therapeutics acquires Surf Bio for up to $400M to expand hyperconcentration capabilities in subcutaneous drug delivery The transaction, closed in late December 2025 and announced January 28, 2026, includes $300M upfront (subject to adjustments) and up to $100M in development/regulatory milestones. Surf Bio’s platform enables high-concentration formulation of monoclonal antibodies, small molecules, and biologics using spray drying, a novel protective excipient, and polymer-based surface tension reduction for protein stability and low-friction delivery via auto-injector. Complementing Halozyme’s Enhanze hyaluronidase and recent Elektrofi/Hypercon acquisition, the technology extends IP into the mid-2040s, opens non-exclusive partnerships across autoimmune, neurology, nephrology, cardiovascular, nucleic acids, and ADCs, and supports rapid home-administration innovations, positioning Halozyme for durable royalty growth and next-generation delivery leadership. (Link)
  4. Illumina (NASD: LMN) acquires SomaLogic and assets from Standard BioTools for $350 million plus milestones to expand proteomics and multiomics leadership The acquisition strengthens Illumina’s position in the fast-growing proteomics market by integrating SomaLogic’s data-driven protein analysis technologies with Illumina’s next-generation sequencing (NGS) and multiomics solutions. Customers will gain access to enhanced tools, including SomaScan assays, DRAGEN software, and Illumina Connected Multiomics, enabling large-scale, flexible, and cost-efficient analysis of complex biological data. The combination supports faster drug discovery and deeper insights into human health. Illumina will maintain continuity for existing SomaLogic customers while expanding global access to the unified platform, investing in scalable growth and innovation across its sequencing and proteomics ecosystems. (Link)
  5. Sword Health acquires Kaia Health in $285M transaction backed by General Catalyst, Khosla Ventures, Transformation Capital and Founders Fund to scale AI-first MSK and pulmonary care in the U.S. and Germany The transaction adds Kaia’s digital musculoskeletal and pulmonary programs and its coveted position in Germany’s reimbursed digital health pathway, giving access to more than 70 million publicly insured individuals. Sword plans to migrate Kaia’s U.S. members to its own AI Care platform, unifying client relationships while extending a wider range of AI-enabled remote services that blend automation with clinician oversight. The combined organization aims use of AI care manager agents to automate administrative tasks and support more accessible virtual care. (Link)
  6. Premise Health acquires Crossover Health, via its financial sponsors OMERS Private Equity, Ares Management, and Ares Capital Corporation BDC creating unified advanced primary and occupational care company The combined organization will operate nearly 900 onsite, nearsite and virtual wellness centers, serving more than 400 employers, unions, tribes and health plans across the U.S. Its integrated model spans advanced primary care, occupational health, behavioral health, care management and navigation, physical therapy and chiropractic, with Premise’s pharmacy services adding chronic condition support and virtual dispensing. Both companies will continue developing alternative payment models, including a primary‑care‑centered health plan, with leadership from both executive teams retained to drive a shared vision of scalable, team‑based primary care that lowers costs and improves outcomes. (Link)
  7. Spring Health to acquire Alma in deal backed by Generation Investment Management, Tiger Global, Thoma Bravo, Cigna Ventures, Optum Ventures, Insight Partners, Tusk Venture Partners, Primary Venture Partners, and Sound Ventures to build AI-enabled lifelong mental health platform and expand nationwide care access The acquisition unites two major digital mental health innovators, combining Spring Health’s AI-driven precision care platform with Alma’s strong national payer relationships and provider infrastructure. The deal will integrate advanced technology, data-informed personalization, and in-network clinician enablement to improve patient outcomes while easing administrative burdens. Both leverage shared resources to advance quality, accessibility, and value across the evolving mental healthcare ecosystem. (Link)
  8. Resonetics to acquire Resolution Medical in a Carlyle, GTCR and Arcline Investment Management–backed deal to expand neuromodulation and structural heart device capabilities The acquisition will add Resolution Medical’s integrated design, engineering and cleanroom manufacturing capabilities for complex Class II and III devices, significantly deepening Resonetics’ presence in neuromodulation, structural heart and interventional cardiology markets. More than 240 employees, including over 100 engineers, will join Resonetics, enabling it to support customers from early product design and NPI through high‑volume production on a larger global footprint. Both organizations emphasize continuity for existing customers while positioning the combined company as a more comprehensive development and manufacturing partner across the full medical device lifecycle. (Link)
  9. Kodiak Solutions acquires BESLER, via its financial sponsor TPG to strengthen revenue recovery and reimbursement capabilities The acquisition brings BESLER’s revenue integrity tools, including Transfer DRG underpayment detection software and managed reimbursement services, onto Kodiak’s existing analytics and automation platform for hospitals and medical practices. Kodiak aims to give health system CFOs deeper, more actionable insight into net revenue, benchmarking, and reimbursement performance while simplifying complex business office workflows. BESLER’s leadership and subject-matter experts, including former CEO Jonathan Besler, are joining Kodiak to help support more than 2,300 hospitals and 350,000 physicians, while founder Philip Besler retires after four decades building the firm. (Link)
  10. Nuwellis (NASD: NUWE) to acquire Rendiatech to expand real-time kidney function monitoring and advance cardiorenal care portfolio The acquisition advances Nuwellis’ move beyond fluid management into continuous renal diagnostics, enhancing its precision cardiorenal care capabilities. Rendiatech’s Clarity™ system provides automated, continuous urine-output monitoring, offering improved accuracy and efficiency over manual methods. The integration of this technology will support earlier kidney stress detection and data-driven clinical decisions in critical care. Nuwellis plans to use its existing commercial and clinical infrastructure to bring Rendiatech’s innovation to market without new sales channels. The transaction, approved by both companies’ boards, marks a key milestone in establishing a more comprehensive cardiorenal platform once customary closing conditions are met. (Link)
  11. Wisp acquires TBD Health to build women-focused national PrEP and sexual health enterprise and hybrid care platform The deal adds a 50‑state sexual health and diagnostics infrastructure, including routine STI/HIV testing, virtual clinical support and deep partnerships with hospital systems and public health organizations. TBD Health’s TelePrEP and diagnostics capabilities, already integrated with partners like Mount Sinai Health System, San Francisco AIDS Foundation and Planned Parenthood Direct, will underpin Wisp’s move beyond direct‑to‑consumer into enterprise and hybrid care models. Together, the companies plan to close major gaps in preventive sexual health—particularly for women—by offering turnkey PrEP and testing solutions that plug into existing clinical workflows and broaden access across consumer, employer and public health channels. (Link)
  12. NOCD acquires Rebound Health, leveraging Noto AI platform to scale virtual OCD and PTSD specialty care The combined organization will expand virtual, evidence-based therapy for OCD and trauma-related disorders nationwide using Noto, an AI-powered infrastructure that supports payer operations, member identification, enrolment, and clinical workflows. NOCD contributes a large, W‑2-employed therapist network delivering more than 1 million OCD sessions annually, supported by tools like AI-assisted notetaking, outcomes tracking, and peer support between visits. Clinical studies of NOCD’s virtual exposure and response prevention model show meaningful symptom reductions for children and teens, while peer interventions increase engagement, and Noto will now also be used to scale Rebound’s PTSD and complex PTSD services across the U.S. (Link)
  13. Premier Radiology Services to acquire National Radiology Solutions (NRAD) to strengthen nationwide teleradiology network and clinical coverage The merger combines two established teleradiology providers to create a stronger national network with enhanced clinical coverage and streamlined operations. By integrating technological infrastructure, administrative systems, and subspecialty expertise, the unified organization will deliver faster, more accurate diagnostic interpretations. NRAD’s team, including founder Robb Kolb, will join the combined company to ensure seamless service for existing clients. The partnership places emphasis on physician autonomy, innovation, and expanding access to high-quality radiology services. Together, the organizations aim to advance patient care standards and improve efficiency for outpatient healthcare providers across the United States. (Link)
  14. Choice Health at Home to acquire Cy-Fair Health Care and Alliant, via its financial sponsor Trive Capital to expand home health and hospice services across key Southwestern markets The acquisition builds on Choice Health at Home’s strategy to enhance integrated home-based care across key Southwestern markets. Both Cy-Fair Health Care in Texas and Alliant in Colorado bring strong clinical reputations and deep community roots, which will now be supported by Choice Health’s broader operational infrastructure and resources. The move strengthens continuity of care for patients and families, with existing staff retained and services uninterrupted. By combining expertise, technology, and compassionate clinical teams, the expanded organization will improve home health and hospice delivery while advancing Choice Health’s mission to provide accessible, patient-centered care across its seven-state network. (Link)
  15. ncgCARE to acquire Broadstep of North Carolina through Carolina Outreach to expand statewide behavioral health services The acquisition broadens ncgCARE’s community-based behavioral health network across eastern and southeastern North Carolina, reinforcing its commitment to accessible, high-quality mental health and substance use care. Broadstep’s existing staff, leadership, and programs will remain in place, ensuring continuity for patients and families. By integrating Broadstep’s operations into Carolina Outreach, ncgCARE will provide expanded operational, clinical, and compliance support to strengthen long-term sustainability and service delivery. The partnership emphasizes stability, quality, and local engagement while enhancing capacity to meet growing behavioral health needs in communities across Gastonia, Lumberton, Jacksonville, Supply, and Wilmington, North Carolina. (Link)

Venture and Other News  

  1. Vaxcyte prices $550M public offering at $50 per share to fund pneumococcal and infectious disease vaccine pipeline The offering includes 11,000,000 shares with a 30-day underwriter option for up to 1,650,000 additional shares, expecting gross proceeds of $550M (before discounts/expenses), closing February 2, 2026. Proceeds will support clinical advancement of lead next-generation pneumococcal conjugate vaccine VAX-31 (Phase 3 adult/Phase 2 infant), VAX-24, plus prophylactic programs for Group A Strep (VAX-A1) and Shigella (VAX-GI). Leveraging its XpressCF cell-free protein synthesis platform for high-fidelity conjugates, Vaxcyte aims to address serious bacterial diseases with broader, more effective immunizations, accelerating late-stage trials, manufacturing scale-up, and progress toward preventing unmet infectious threats. (Link)
  2. Veradermics and Eikon Therapeutics file for IPOs targeting up to $181M and $318M amid biotech market reopening Veradermics (NYSE: MANE) seeks approximately $181M to advance Phase III VDPHL01 (extended-release oral minoxidil) for pattern hair loss in men and women, supporting approval, commercialization, physician education, brand awareness, supply chain, and infrastructure in dermatology. Eikon Therapeutics (Nasdaq: EIKN), led by former Merck executive Roger Perlmutter, targets up to $318M (with overallotment) primarily for clinical progression of TLR7/8 agonists EIK1001 (melanoma) and EIK1003 (non-small cell lung cancer), plus selective PARP1 inhibitors and WRN helicase assets in challenging oncology indications. The January 2026 filings signal renewed investor confidence post-2025 slowdown, enabling late-stage advancement, pipeline expansion, and public-market capitalization for these high-potential biotechs. (Link)
  3. Cellares raises $257M in Series D round led by Eclipse and BlackRock with participation from T. Rowe Price, Gates Frontier, Duquesne Family Office, Intuitive Ventures, DC Global Ventures and DFJ Growth to scale global cell therapy manufacturing The new funding supports Cellares’ global expansion as it prepares for commercial-scale cell therapy production by 2027. The company will build new manufacturing facilities in the Netherlands and Japan, complementing sites in New Jersey and South San Francisco. Its automated “Cell Shuttle” system enables end-to-end cell therapy production, addressing industry bottlenecks through scalable, high-tech infrastructure. With increasing demand and regulatory validation, Cellares is positioning itself as a leading integrated developer and manufacturer supporting global biopharma partners, including Bristol Myers Squibb. The financing advances its mission to industrialize cell therapy and move toward a public listing. (Link)
  4. Tenpoint Therapeutics raises $235M from Janus Henderson, EQT Nexus, Hillhouse, British Business Bank, EQT Life Sciences, Sofinnova Partners, F-Prime, Eight Roads, Qiming Venture Partners USA, AdBio, Wille, and Hercules Capital to accelerate commercialization of YUVEZZI™ The financing strengthens Tenpoint Therapeutics’ position for the commercial launch of YUVEZZI™, the first FDA-approved dual-agent, once-daily eye drop for presbyopia. The funding includes an $85 million Series B round and a $150 million credit facility, providing the capital needed to scale manufacturing, distribution, and marketing. Tenpoint aims to meet the needs of millions affected by age-related vision decline while delivering a differentiated treatment backed by strong clinical data and safety performance. The company’s leadership is focused on driving YUVEZZI™’s successful rollout and expanding access to innovative ophthalmic solutions. (Link)
  5. Breakthru Medicine emerges from stealth with $60M Series A financing to advance disruptive cancer therapeutics The funding, supported by investors including Dave Morehead (Baylor University endowment), Fred Eshelman (Eshelman Ventures), and Mark Gergen, enables Breakthru Medicine to build its tumor-agnostic platform targeting hard-to-drug cancers through small molecules, next-generation antibody-drug conjugate payloads, and a novel molecular glue approach. The company prioritizes patient-first development by rigorously selecting breakthrough candidates early and eliminating non-viable programs. The capital accelerates pipeline progression and platform expansion to redefine therapeutic possibilities for oncology indications. (Link)
  6. TRexBio raises $50M from Janus Henderson Investors, Alexandria Venture Investments, Avego BioScience Capital, Eli Lilly, Johnson & Johnson Innovation JJDC, Pfizer Ventures and SV Health Investors to advance tissue-targeted Treg immunology pipeline The financing supports TRexBio’s ongoing clinical and preclinical programs focused on tissue-specific regulatory T cell therapies for autoimmune and inflammatory diseases.. Leveraging its Deep Biology Platform, TRexBio maps tissue Treg behavior to uncover novel therapeutic targets. The investment underscores confidence in the company’s precision immunoregulatory approach aimed at delivering more effective, durable treatments for diseases such as atopic dermatitis and other inflammatory disorders. (Link)
  7. Prenosis secures $20M Series A led by PACE Healthcare Capital with UC Investments, UCI Health Ventures, Labcorp Venture Fund, GHIC, Illinois DCEO, and Carle Health, plus $20M BARDA contract to advance AI diagnostics and therapeutics The combined $40 million will drive Prenosis’ development of biology-based, AI-powered diagnostic and therapeutic tools for critical care conditions such as sepsis, ARDS, and acute kidney injury. The BARDA-funded program will include a pivotal clinical trial evaluating an AI-enabled steroid companion diagnostic for severe respiratory infections. These initiatives strengthen Prenosis’ mission to personalize treatment by combining advanced diagnostics with targeted therapeutics, marking a major step in improving outcomes for critically ill patients through precision care. (Link)
Spenser Lin No Comments

Healthcare News, Deals, and Investments Update Jan 26th, 2026

LECO_Weekly-Healthcare-News_1-26-2026Download
  1. Winter Storm Fern Cripples Half the Country This Weekend
    • CNBC: $100B expected economic loss and damages from storm (Link) 
    • CNBC: Transportation Sec. Duffy says air travel will return to normal by Wednesday (Link) 
    • The Weather Channel: Winter Storm Fern Turns Deadly In Louisiana, Outages For Hundreds Of Thousands Vulnerable To Ice, Snow (Link) 
    • National Public Radio: As the winter storm rages, here’s what to know in your state(Link)
  2. GSK (NYSE:GSK) pays $2.2B to acquire Rapt Therapeutics (NASD:RAPT) and Food Allergy Antibody Ozureprubart GSK is acquiring Rapt Therapeutics for $58 per share, gaining global (ex‑China) rights to ozureprubart, an extended‑half‑life anti‑IgE antibody being studied as a 12‑weekly prophylactic treatment for food allergies. Unlike currently approved IgE inhibitors that require injections every 2–4 weeks, ozureprubart aims to offer sustained protection with less frequent dosing while targeting the same validated pathway as Xolair. The deal follows Rapt’s strategic pivot away from its CCR4 inhibitor program after clinical setbacks and positions ozureprubart for phase 2 readout in 2027 and a planned phase 3 program, backed by GSK’s global development and commercialization infrastructure. (Link)
  3. BioCryst (NASD: BCRX) acquires Astria Therapeutics (NASD:ATXS) in $700M deal to Build Comprehensive Hereditary Angioedema Treatment Platform The transaction adds Navenibart, a long-acting plasma kallikrein inhibitor in Phase 3, which is being developed as a prophylactic HAE treatment with every‑three or every‑six month dosing to improve patient convenience and attack control. BioCryst now pairs its existing oral therapy ORLADEYO with a potential injectable option to give clinicians more flexibility in tailoring care. The deal also brings STAR0310, an early atopic dermatitis program for which strategic options will be explored, and augments BioCryst’s leadership with Astria’s former CEO joining the board and a senior development leader taking charge of technical operations. (Link)
  4. Georgia ProtonCare Center, Inc. Files Chapter 11 to Facilitate Competitive Sale Process and Enters Into Asset Purchase Agreement With Emory Healthcare Georgia ProtonCare Center (GPCC), owner of Georgia’s only proton therapy cancer treatment facility in Midtown Atlanta, has filed for Chapter 11 bankruptcy to facilitate a court-supervised sale process and ensure uninterrupted patient care. The company has signed an asset purchase agreement with Emory Healthcare (via Emory University Hospital Midtown) as the stalking horse bidder to acquire substantially all assets, with Emory clinicians already providing daily treatment at the center. GPCC aims to complete the competitive sale by Q2 2026, prioritizing seamless continuation of precision proton therapy services for cancer patients while operations continue as usual under court-approved funding. (Link)
  5. KidsChoice Announces Majority Investment from Aquitaine Capital to Support Growth and Clinical Excellence KidsChoice, an Oklahoma-based provider of clinic-centered autism and pediatric therapy services including ABA, speech, and occupational therapy, has secured a majority investment from women-owned private equity firm Aquitaine Capital to fuel expansion, enhance clinical excellence, and strengthen infrastructure. The partnership supports thoughtful growth through new clinic openings, strategic M&A, and complementary offerings while prioritizing individualized, outcomes-driven care for children and families. (Link)
  6. Community Health Systems Sells Crestwood Medical Center to Huntsville Hospital Health System in $450M Deal The transaction will transfer Crestwood Medical Center, a 180‑bed acute care hospital in Huntsville, Alabama, along with a freestanding emergency department in Harvest and multiple clinics and outpatient assets, to a regional nonprofit operator. Crestwood’s roughly 1,000 employees will continue normal operations with no planned changes to services or medical staff privileges during the transition. Huntsville Hospital Health System, already a major 14‑hospital network across northern Alabama and southern Tennessee, views the deal as a way to better coordinate local care as Huntsville’s population rapidly grows, while the seller continues its strategy of divesting assets to strengthen its financial position. (Link)
  7. BioStem Technologies (OTC: BSEM) and BioTissue sign Up to $40M Surgical and Wound Care Asset DealThe transaction adds BioTissue’s Neox and Clarix placental- and umbilical‑tissue allograft product lines, along with a national direct and independent sales force and key group purchasing organization contracts, giving BioStem an immediate presence in hospital inpatient and outpatient settings. The acquired surgical and wound care assets, which generated about $29 million in 2025 sales, broaden BioStem’s chronic and acute wound care portfolio and create entry into high‑value segments such as burns and soft‑tissue repair. Deal terms include an upfront $15 million cash payment plus up to $25 million in potential regulatory and commercial milestone payments. (Link)
  8. Harmony Healthcare IT acquires Blue Elm, via its financial sponsor Novacap to build Comprehensive MEDITECH Data Lifecycle Platform Harmony Healthcare IT has acquired Blue Elm to offer MEDITECH hospitals a single, end-to-end partner for data extraction, conversion, migration, archiving, optimization, and real-time access across all MEDITECH versions. The combined capabilities help hospitals retire costly legacy systems, strengthen data integrity, and improve accessibility as they upgrade or transition EHR platforms. By unifying services under one organization and relying on U.S.-based resources instead of offshore outsourcing, the company aims to shorten complex project timelines, enhance security and quality, and better support hospitals under pressure to improve care quality while reducing operating costs. (Link)
  9. PhaseWell Research acquires Bio Behavioral Health Partner, via its financial sponsor Shore Capital Partners to expand Community-Based Neuropsychiatric Clinical Trials The acquisition will strengthen PhaseWell’s national network of community clinical research sites focused on neurologic and psychiatric disorders. The collaboration aims to broaden patient access to neuropsychiatric trials by leveraging BBH’s experience in community-based studies and PhaseWell’s nationwide platform and infrastructure. Together, the organizations plan to support sponsors with reliable patient enrolment, strong operational execution, and high-quality data while advancing next-generation CNS therapeutics across complex therapeutic areas, including oncology, cardiovascular/metabolic conditions, and dermatology. (Link)
  10. Pair Team acquires Town Square to Advance AI-Enabled Community Care for Medicare and Medicaid Beneficiaries The acquisition combines an AI-driven medical group with a social care coordination platform to better integrate clinical, behavioral, and social services for underserved populations. Technology will orchestrate complex, cross-setting care tasks so human teams can concentrate on clinical decisions, hands-on support, and relationships with patients and local organizations. Town Square’s founder will lead network expansion and community partnerships within the new structure, which emphasizes responsible AI, robust outcomes measurement, and investment in community-based infrastructure to extend whole-person care to people historically excluded from the healthcare system. (Link)
  11. Aspen Surgical expands Infection Prevention Portfolio with acquisition of Ruhof Healthcare, via its financial sponsors Linden and Audax Private Equity The buyer is adding enzymatic detergents, cleaning verification tools, and automated and manual instrument and endoscope reprocessing solutions to deepen its presence in operating rooms, sterile processing, and endoscopy settings. Ruhof’s portfolio, including Endozime detergents, ScopeValet single-use consumables, CleanRead ATP contamination monitoring, and instrument refurbishment services, will bolster the SPD360 Performance Solutions platform and complement existing brands such as Symmetry, Bookwalter, and Precept. The transaction covers all Ruhof operations, brands, and product lines, with integration set to begin immediately and no near-term disruption expected for customers, suppliers, or employees. (Link)
  12. TridentCare acquires DispatchHealth Imaging Unit to Grow National Portable Diagnostics Network The acquisition adds a multistate mobile X‑ray and ultrasound operation that serves patients at home, in post‑acute facilities, and in correctional settings, expanding TridentCare’s reach and capacity. By integrating these imaging teams and customers into its national infrastructure, TridentCare aims to speed response times, improve scheduling flexibility, and deliver more consistent service quality for clinicians and patients. DispatchHealth will continue focusing on providing complex care in the home and will coordinate imaging through technology and partnerships so patients and providers experience seamless, integrated services. (Link)
  13. Morris & Dickson Completes Transaction to Acquire Prodigy Health Morris & Dickson (M&D), the nation’s largest independent wholesale and specialty pharmaceutical distributor, has completed its acquisition of Prodigy Health, a specialty pharmaceutical distribution and services company focused on plasma-derived therapies. The transaction expands M&D’s specialty portfolio, broadens access to plasma therapies for hospitals, clinics, infusion centers, and alternative care sites nationwide, and strengthens its independent platform for manufacturers through a compliance-first approach. (Link)
  14. Main Post Partners and HomeWell Leadership acquire HomeWell Franchising to Accelerate Senior In‑Home Care Growth The deal pairs a national non‑medical home care franchisor with a private equity firm experienced in franchising and consumer service brands, aiming to fuel the next phase of expansion. The partners emphasize a “partnership, not ownership” philosophy, focusing on close collaboration with franchisees and caregivers to scale services while preserving mission and culture. Building on several years of rapid revenue growth and record franchise development, the company plans to invest in tools, resources, and support that help local agencies grow and better serve seniors and homebound individuals in their communities. (Link)

Venture and Other News  

  1. Zarminali Paediatrics raises $110M in Series A funding led by Healthier Capital, with participation from General Catalyst, K2 HealthVentures, and Boston Children’s Hospital to expand integrated paediatric care footprint The company will use the new capital to scale its proprietary tech platform, enter additional states and open de novo clinics while continuing to acquire established paediatric groups. Its model centers on a single branded multispecialty practice that co-locates clinics with urgent care, directly employing both paediatricians and specialists to coordinate care across the full continuum outside the hospital. Since launching in 2024, Zarminali has rapidly expanded to 28 clinics in eight states and plans at least 15 new sites in 2026, while laying groundwork for future value-based arrangements and building analytics to track clinician performance and patient outcomes. (Link)
  2. Mendra launches with $82M Series A co-led by OrbiMed, 8VC, and 5AM Ventures, with participation from Lux Capital and Wing VC to advance AI-driven rare disease therapeutics Mendra will use the oversubscribed financing to acquire and develop an initial portfolio of high-potential rare disease assets while applying AI to speed patient identification, trial enrollment and global market access. The company is built to modernize how rare disease medicines are developed and commercialized so they reach underserved patients more efficiently worldwide. A veteran leadership team with deep experience in rare disease drug development, global commercialization and AI—drawn from organizations such as BioMarin, Modis Therapeutics, Escient Pharmaceuticals, Palantir and Bayer—will guide strategy across asset selection, clinical execution and business development. (Link)
  3. AnswersNow raises $40M in Series B funding led by HealthQuest Capital, with participation from Left Lane Capital and Owl Ventures to Scale AI-Enabled Virtual Autism Therapy The company will use the new capital to expand its platform, double clinical headcount, add senior leaders and launch new service lines to meet surging demand for autism support. Its AI-driven model pairs families across the U.S. with Master’s- and PhD-level BCBAs for targeted, parent-mediated virtual ABA, cutting weekly therapy time from 30+ hours to about 4–5 while sustaining strong clinical gains. Outcomes data show high family-reported improvements, substantial cost savings for payors and a consistently strong satisfaction score, with forthcoming research in 2026 intended to further validate clinical and economic impact. (Link)
  4. BrightInsight secures $13M investment from Eclipse, General Catalyst, Insight Partners, Mayo Clinic and New Leaf Venture Partners to scale its AI-enabled medication adherence platform The company will deploy the capital to expand its AI-enabled persistence and adherence solutions, including a co-developed Patient App used across multiple diseases and therapies worldwide. By leveraging real-world data and advanced analytics, the platform targets chronically low adherence rates, aiming to predict churn and trigger personalized interventions that keep patients on therapy. BrightInsight reports strong patient engagement and one-year retention across programs and plans to deepen its product roadmap, broaden disease and biopharma partnerships, and add support for caregivers and nurse educators to ease pressure on health systems. (Link)
  5. McKinsey & Co Released their Annual Healthcare Outlook Report. To remain competitive in 2026 and beyond, healthcare leaders must improve performance, embrace technology and rethink traditional care models (Link)
  6. IPO Watchlist
    • Once Upon a Farm — Organic children’s food company co-founded by Jennifer Garner, is targeting a valuation of up to $764.4 million in its upcoming U.S. IPO on the NYSE under the ticker OFRM. (Link)
    • Kallyope — New York City-based biotechnology company specializing in novel therapeutics targeting the gut-brain axis and neural circuits.
    • Kardium — Vancouver area based medical device company focused on cardiac electrophysiology solutions; develops advanced catheter-based systems for the diagnosis and minimally invasive treatment of atrial fibrillation.
    • Tenpoint Therapeutics — London, UK-headquartered (with U.S. operations in Seattle and Irvine) ophthalmic biotechnology company dedicated to age-related vision restoration therapies.
    • Vensure Employer Solutions — Chandler, AZ -based professional employer organization (PEO) and provider of human capital management (HCM) technology serving the healthcare and broader employer ecosystem.